Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) Director Gary W. Tempo bought 15,000 shares of the agency’s inventory in a transaction that occurred on Wednesday, July thirtieth. The shares had been purchased at a mean value of $2.45 per share, with a complete worth of $36,750.00. Following the completion of the acquisition, the director owned 1,345,676 shares of the corporate’s inventory, valued at roughly $3,296,906.20. This commerce represents a 1.13% enhance of their possession of the inventory. The acquisition was disclosed in a submitting with the Securities & Trade Fee, which could be accessed via the SEC website.
Cardiff Oncology Inventory Efficiency
NASDAQ:CRDF opened at $2.37 on Friday. The inventory has a fifty day transferring common value of $3.60 and a two-hundred day transferring common value of $3.50. The inventory has a market capitalization of $157.67 million, a price-to-earnings ratio of -2.72 and a beta of 1.52. Cardiff Oncology, Inc. has a 1 12 months low of $2.01 and a 1 12 months excessive of $5.64.
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) final launched its quarterly earnings information on Tuesday, July twenty ninth. The corporate reported ($0.21) earnings per share (EPS) for the quarter, lacking the consensus estimate of ($0.19) by ($0.02). The enterprise had income of $0.12 million throughout the quarter, in comparison with analysts’ expectations of $0.11 million. Cardiff Oncology had a damaging return on fairness of 77.94% and a damaging internet margin of 9,344.14%. On common, analysts predict that Cardiff Oncology, Inc. will publish -0.99 EPS for the present 12 months.
Institutional Inflows and Outflows
A lot of hedge funds have just lately made adjustments to their positions within the firm. Blair William & Co. IL elevated its place in shares of Cardiff Oncology by 44.1% within the second quarter. Blair William & Co. IL now owns 2,524,118 shares of the corporate’s inventory valued at $7,951,000 after shopping for a further 772,844 shares within the final quarter. Orbimed Advisors LLC bought a brand new place in shares of Cardiff Oncology within the fourth quarter valued at $6,677,000. Adage Capital Companions GP L.L.C. elevated its place in shares of Cardiff Oncology by 11.8% within the first quarter. Adage Capital Companions GP L.L.C. now owns 1,445,000 shares of the corporate’s inventory valued at $4,537,000 after shopping for a further 152,692 shares within the final quarter. Acorn Capital Advisors LLC bought a brand new place in shares of Cardiff Oncology within the fourth quarter valued at $6,260,000. Lastly, Geode Capital Administration LLC elevated its place in shares of Cardiff Oncology by 5.9% within the fourth quarter. Geode Capital Administration LLC now owns 982,878 shares of the corporate’s inventory valued at $4,266,000 after shopping for a further 54,646 shares within the final quarter. Hedge funds and different institutional buyers personal 16.29% of the corporate’s inventory.
Analysts Set New Value Targets
CRDF has been the topic of a number of latest analysis stories. HC Wainwright elevated their value goal on Cardiff Oncology from $17.00 to $18.00 and gave the inventory a “purchase” score in a report on Friday, Might ninth. William Blair reiterated an “outperform” score on shares of Cardiff Oncology in a analysis report on Wednesday, June 18th. LADENBURG THALM/SH SH started protection on Cardiff Oncology in a analysis report on Tuesday, July eighth. They issued a “purchase” score and a $19.00 value goal for the corporate. Lastly, Jefferies Monetary Group started protection on Cardiff Oncology in a analysis report on Tuesday, June twenty fourth. They issued a “maintain” score and a $3.50 value goal for the corporate. One analysis analyst has rated the inventory with a maintain score and 5 have issued a purchase score to the corporate’s inventory. In accordance with MarketBeat, the corporate has a mean score of “Average Purchase” and a mean goal value of $11.70.
Get Our Latest Analysis on Cardiff Oncology
Cardiff Oncology Firm Profile
Cardiff Oncology, Inc, a clinical-stage biotechnology firm, develops novel therapies to deal with numerous cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to therapy a spread of strong tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic most cancers, in addition to investigator-initiated trials in triple damaging breast most cancers and small cell lung most cancers; and TROV-054 is a Section 1b/2 for FOLFIRI and bevacizumab.
See Additionally
This prompt information alert was generated by narrative science expertise and monetary information from InsiderTrades.com with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by InsiderTrades.com’s editorial group previous to publication. Please ship any questions or feedback about this story to [email protected].
